Management of Mitral Stenosis with Atrial Fibrillation

Immediate Assessment and Stabilization

If hemodynamically unstable, the American College of Cardiology recommends immediate electrical cardioversion with concurrent intravenous heparin bolus followed by continuous infusion 1
If hemodynamically stable, the European Heart Journal suggests proceeding to anticoagulation and rate control strategy 2

The American College of Cardiology recommends targeting an INR of 2.5-3.5, with monitoring weekly during initiation and monthly when stable 1
The European Heart Journal states that direct oral anticoagulants are contraindicated in moderate-to-severe mitral stenosis due to lack of safety data 2
Anticoagulation for at least 3-4 weeks before cardioversion is recommended by the American College of Cardiology and the European Heart Journal 1, 3

The European Heart Journal recommends beta-blockers as first-line rate control agents, controlling rate at rest and during exercise 2, 4
Non-dihydropyridine calcium channel blockers may be used if LVEF >40%, according to the European Heart Journal 2, 3
Digoxin may be added as adjunct therapy but should not be used as sole agent for rate control, as stated by the Journal of the American College of Cardiology 4, 1

The European Heart Journal recommends transthoracic echocardiography to assess mitral valve area, mean gradient, and valve morphology 5, 6
Severe mitral stenosis is defined as MVA ≤1.0 cm², according to the European Heart Journal 5, 6
Percutaneous mitral balloon commissurotomy is first-line treatment for symptomatic severe MS if valve morphology is favorable, as stated by the European Heart Journal 5, 6

The European Heart Journal discusses rhythm control options, including cardioversion, antiarrhythmic drugs, or catheter ablation, to reduce symptoms and prevent AF progression 2, 3
AF ablation success rates are lower in mitral stenosis patients, and consideration of AF ablation during mitral valve surgery in experienced centers is recommended by the European Heart Journal 2, 7

The European Heart Journal recommends continuing warfarin indefinitely with INR 2.5-3.5, regardless of whether sinus rhythm is restored, due to high thromboembolic risk from mitral stenosis itself 2, 3
Maintaining INR in therapeutic range >70% of the time is suggested by the European Heart Journal 2
Periodic clinical and echocardiographic follow-up is recommended by the European Heart Journal to reassess for progression of mitral stenosis, development of symptoms, or need for intervention 5, 6, 2

The American College of Cardiology recommends mandatory oral anticoagulation with warfarin targeting an INR of 2.5-3.5 for patients with mitral stenosis and atrial fibrillation, due to the high risk of thromboembolism 8, 9
A target INR of 2.5-3.5 (or higher) is recommended for patients with rheumatic mitral stenosis and atrial fibrillation, which is a higher intensity target than standard atrial fibrillation 10, 8, 9
The American College of Cardiology suggests monitoring INR weekly during initiation, then monthly when stable 8, 9

The American College of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel antagonists as first-line agents for ventricular rate control in patients with mitral stenosis and atrial fibrillation 10, 8, 11
The American College of Cardiology suggests administering intravenous beta-blockers or calcium channel antagonists to slow rapid ventricular response in the acute setting, with caution in patients with hypotension or heart failure 10, 8
Immediate electrical cardioversion is indicated for hemodynamically unstable patients with symptomatic hypotension, angina, or heart failure unresponsive to pharmacological measures 8, 12, 13

The American College of Cardiology advises against using digoxin as the sole agent for rate control in paroxysmal atrial fibrillation 11, 9
The American College of Cardiology recommends avoiding calcium channel blockers in decompensated heart failure, as they may exacerbate hemodynamic compromise 11, 9

The American College of Cardiology suggests immediately assessing hemodynamic stability, and if unstable, performing immediate electrical cardioversion with concurrent heparin 12, 13
The American College of Cardiology recommends initiating oral anticoagulation with warfarin targeting INR 2.5-3.5 10, 8, 9

The American College of Cardiology advises against failing to use higher-intensity anticoagulation (INR 2.5-3.5) specific to mitral stenosis, rather than standard AF targets 10, 8, 9
The American College of Cardiology recommends against using digoxin as sole agent for rate control in paroxysmal atrial fibrillation 11, 9
The American College of Cardiology advises against administering calcium channel blockers in patients with decompensated heart failure 11, 9